SAN DIEGO, June  26, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (NASDAQ:LSTA) on behalf of investors who suffered losses and whether those losses may be recoverable under

LSTA

Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing

Johnson Fistel investigation raises Lisata risk amid Kuva financing uncertainty

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, June  26, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (NASDAQ:LSTA) on behalf of investors who suffered losses and whether those losses may be recoverable under</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Johnson Fistel&#039;s probe into Lisata Therapeutics (LSTA) centers on potential securities-law violations tied to Kuva&#039;s takeover. Key disclosures show financing for the tender offer remains uncertain, with multiple amendments and delays. The investigation adds legal and deal-closure risk, likely increasing near-term volatility in LSTA shares.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel probes Lisata (LSTA) for potential securities-law violations.</li><li>Kuva&#039;s cash offer with CVRs faces financing uncertainty, delaying tender.</li><li>Financing absence disclosed; material to security holders&#039; tender decisions.</li><li>Tender offer commenced June 10, 2026; funding remains uncommitted.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Lisata Therapeutics, Inc. (LSTA)</strong>: Subject of Johnson Fistel securities-law investigation; potential impact on closing and shareholder value.</li><li><strong>Kuva Acquisition Corp. (N/A)</strong>: Tender-offer counterparty; financing delays and potential impact on Lisata value.</li><li><strong>Kuva Labs, Inc. (N/A)</strong>: Related entity; financing discussions affecting offer funding.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal; the article focuses on a securities-law investigation related to a pending M&amp;A tender offer, with financing risk as a key driver of price movement.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Financing updates from Kuva are primary driver.</li><li>Delay or termination risk could depress LSTA shares.</li><li>Legal investigation may trigger volatility independent of the deal.</li><li>Any sign of closing by Q3 2026 could restore confidence but remains uncertain.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Jan 21, 2026: Lisata announced binding term sheet to be acquired by Kuva; cash $4.00 per share + CVRs.</li><li>Mar 6, 2026: Definitive merger; tender offer at $5.00 per share + one CVR; no financing condition.</li><li>Apr 15, 2026: Kuva seeking alternative financing; no assurance tender would commence.</li><li>Jun 1, 2026: Tender offer not commenced due to financing negotiations.</li><li>Jun 10, 2026: Tender offer commenced; $4.00 cash + one CVR; no committed financing; closing expected Q3 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term, LSTA faces downside risk from deal delay and financing uncertainty; monitor updates.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, June  26, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LSTA">LSTA</a>) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.</p>  <p><strong>Lisata Therapeutics Investors: Contact Johnson Fistel</strong><br></br>If you purchased Lisata Therapeutics securities and suffered losses on your investment, you are encouraged to <a href="https://www.globenewswire.com/Tracker?data=1Es6RFDlKh63Wa_wVoJHyhNF03yzaSTRnRE4Ujfhn6ifH1_3mL7Hy-FItklqw-7zn_Cug4BxiAFmC4pgG3DCXcbf9ugDSb5pJs4o-pzmhW_i9pPFUE8QtxnOK5qefvP-Rj34PL117MzJ_qQ8d1701t2zLXgQvObsqBO7xyaGuUfBhWQBmgxBKTyGbidhq_SO" rel="nofollow" target="_blank">click here to join the investigation</a>.</p>  <p>For more information, contact Jim Baker at <a href="https://www.globenewswire.com/Tracker?data=mwHhm3W08nWA1DYAOJoP3c6weCZ7vQf03jgJ93JEkNpY6D5syMq-EaVwvJj_hpKoWWImc3QVRkfpkxx7d15rquSCkBcl9d5HUPsXCUvtI5Y=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>  <p>There is no cost or obligation to you.</p>  <p><strong>Background of the Investigation</strong><br></br>On January 21, 2026, Lisata announced that it had entered into a binding term sheet to be acquired by Kuva Labs, Inc. Under the proposed transaction, Kuva would commence a tender offer to acquire all outstanding shares of Lisata common stock for $4.00 per share in cash, plus contingent value rights.</p>  <p>On March 6, 2026, Lisata announced that it had entered into a definitive merger agreement with Kuva. Under the terms of the agreement, Kuva would commence a tender offer to acquire all issued and outstanding shares of Lisata common stock for $5.00 per share in cash, plus one contingent value right per share. Lisata further disclosed that the transaction was expected to close in the second quarter of 2026 and that the merger agreement did not include a financing condition.</p>  <p>Then, on April 15, 2026, Lisata filed a Form 8-K disclosing that Kuva Acquisition Corp. had not yet commenced the tender offer. Lisata further disclosed that Kuva was "currently seeking alternative sources of financing on terms more favorable to Parent to fund the tender offer," and that Kuva intended to launch the tender offer "when its financing is finalized." Lisata also stated that there could be no assurance as to when the tender offer would commence, if at all.</p>  <p>On June 1, 2026, Lisata and Kuva disclosed that the tender offer would not commence on June 1, 2026, as previously announced, due to continuing negotiations regarding financing of the offer.</p>  <p>On June 8, 2026, Lisata disclosed another amendment to the merger agreement. Among other things, Lisata disclosed that Kuva Acquisition Corp. acknowledged that "the absence of committed financing as of the date of the Amendment constitutes information that is material to security holders of the Company for purposes of their decision whether to tender their shares."</p>  <p>On June 10, 2026, Lisata announced that Kuva Acquisition Corp. had commenced the tender offer. Under the revised terms, Lisata stockholders would receive $4.00 per share in cash, plus one non-tradeable contingent value right representing the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to the achievement of specified milestones. Lisata further disclosed that, as of the commencement of the offer, Parent and Purchaser did not have committed financing to fund the offer price, and that there could be no assurance such financing would be obtained. Lisata also disclosed that closing was expected to occur in the third quarter of 2026, subject to satisfaction of the offer conditions.</p>  <p>In light of these disclosures, Johnson Fistel is investigating whether Lisata Therapeutics complied with federal securities laws. If you suffered losses, or are a long-term holder of Lisata Therapeutics stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder litigation involving securities fraud, breaches of fiduciary duties, and other violations of state and federal law.</p>  <p>Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.</p>  <p>Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. This press release may be considered a promotional communication. The attorney responsible for this communication is Frank J. Johnson.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471<br></br><a href="https://www.globenewswire.com/Tracker?data=mwHhm3W08nWA1DYAOJoP3c6weCZ7vQf03jgJ93JEkNrbggk7qmPNGH0IKwsjporNsp56xMyLyXDzrLvRiSXgjOKTyiNr8_85kMnTRB1cISs=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> &#x7C; <a href="https://www.globenewswire.com/Tracker?data=5K-X-GIjs_tASLg9Mzjexj3OZl-tTujK558yuOkZzeW6x-ypeftbxGKawXAE2xuEP6f6KtvXtxUXrwzRoHpBy2k3zznSi9Jg-_lHGTNHrIkNPMiNSArMmVwkaHSEmmni" rel="nofollow" target="_blank">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1MzI4MyM3NjU5MDQ3IzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NzFmYzU3ZjgtNTRkNC00YTY4LTgwYjEtNTc0OTE2NDlmMzBlLTExOTMzNTgtMjAyNi0wNi0yNi1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Johnson Fistel's probe into Lisata Therapeutics (LSTA) centers on potential securities-law violations tied to Kuva's takeover. Key disclosures show financing for the tender offer remains uncertain, with multiple amendments and delays. The investigation adds legal and deal-closure risk, likely increasing near-term volatility in LSTA shares.

Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News